Trials / Completed
CompletedNCT02226965
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Sierra Oncology LLC - a GSK company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PNT2258 |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-07-11
- Completion
- 2018-08-22
- First posted
- 2014-08-27
- Last updated
- 2023-06-29
- Results posted
- 2020-04-22
Locations
27 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT02226965. Inclusion in this directory is not an endorsement.